Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Sym021 |
Synonyms | |
Therapy Description |
Sym021 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3822, PMID: 31046547, PMID: 31754392). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Sym021 | Sym-021|Sym 021 | Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 119 | Sym021 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3822, PMID: 31046547, PMID: 31754392). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03311412 | Phase I | Sym021 | Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | Completed | USA | CAN | 0 |